openPR Logo
Press release

Estrogen Receptor Market Pipeline Review, H2 2017

09-22-2017 12:44 PM CET | Health & Medicine

Press release from: MarketResearchReports.biz

"The Report Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report Estrogen Receptor - Pipeline Review, H2 2017, outlays comprehensive information on the Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

View Report @ https://www.marketresearchreports.biz/reports/1329520/estrogen-receptor-er-alpha-or-estradiol-receptor-or-nuclear-receptor-subfamily-3-group-a-member-1-or-nr3a1-or-esr1-pipeline-review-h2-2017-market-research-reports

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Estrogen receptor alpha (ERA) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR1. It is involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. It decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displaces RELA/p65 and associated co-regulators from the promoter. It recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 3, 1, 6 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health, Central Nervous System, Dermatology and Metabolic Disorders which include indications Breast Cancer, Metastatic Breast Cancer, Endometriosis, Female Contraception, Vasomotor Symptoms of Menopause (Hot Flashes), Bipolar Disorder (Manic Depression), Ductal Carcinoma In Situ, Encephalopathy, Hormone Sensitive Breast Cancer, Metastatic Prostate Cancer, Multiple Sclerosis, Neurology, Osteoporosis, Ovarian Cancer, Prostate Cancer, Vaginal Atrophy (Atrophic Vaginitis) and Vulvar Atrophy.

Furthermore, this report also reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Get Sample Copy Of This Report @
https://www.marketresearchreports.biz/sample/sample/1329520

Scope

- The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)
- The report reviews Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Estrogen Receptor Market Pipeline Review, H2 2017 here

News-ID: 734403 • Views: 144

More Releases from MarketResearchReports.biz

Global Automotive Augmented Reality and Virtual Reality Market Breakdown Data by …
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Automotive Augmented Reality and Virtual Reality Market Insights, Forecast to 2025” Augmented reality (AR) is a technology that adds on or layers digital media, such as touch feedback, graphics, 3D models, and sound, on a real world environment to enhance user experience and interaction. Virtual reality (VR) is a computer simulated reality that is achieved through replicating an environment
Global Artificial Intelligence in Transportation Market Breakdown Data by Region …
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Artificial Intelligence in Transportation Market Insights, Forecast to 2025” Global Artificial Intelligence in Transportation market size will reach million US$ by 2025, from million US$ in 2017, at a CAGR of during the forecast period. In this study, 2017 has been considered as the base year and 2018-2025 as the forecast period to estimate the market size for Artificial
Global Automotive Wind Tunnel Testing Equipment Market Forecast to 2025: By Prod …
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Automotive Wind Tunnel Testing Equipment Market Insights, Forecast to 2025” Global Automotive Wind Tunnel Testing Equipment market size will reach million US$ by 2025, from million US$ in 2017, at a CAGR of during the forecast period. In this study, 2017 has been considered as the base year and 2018-2025 as the forecast period to estimate the market size
Global Automotive Beauty Industry Analysis and Forecast 2018-2025
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Automotive Beauty Market Insights, Forecast to 2025” This industry study presents the global Automotive Beauty market size, historical breakdown data (2013-2018) and forecast (2018-2025). The Automotive Beauty production, revenue and market share by manufacturers, key regions and type; The consumption of Automotive Beauty in volume terms are also provided for major countries (or regions), and for each application and product

All 5 Releases


More Releases for Receptor

Interleukin Receptor Modulators Therapeutics - Pipeline Analysis 2019
Interleukin receptors are a group of cytokine receptors that are expressed by leukocytes. Interleukin receptors play an important role in the functioning of the immune system. However, with complete knowledge of their role in pathogenesis of different diseases from allergic reactions to autoimmune disorders and even cancer makes these interleukin receptors an attractive target among different available treatment modalities. Download the sample report @ https://www.pharmaproff.com/request-sample/1204 Immune-modulatory role of interleukins as well
Tumor Necrosis Factor Receptor
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Tumor Necrosis Factor - Pipeline Review, H2 2017” Tumor Necrosis Factor Overview Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) …
"The Report Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)-Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Gh …
"The Report Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipe …
"The Report Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype Pipeline Review, H2 2017'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 11 molecules. Out of which approximately 10
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Recept …
Market Research Hub (MRH) has added a new report titled “Calcitonin Gene Related Peptide Type 1 Receptor, Pharmaceutical Pipeline Research Report” to its vast data repository. Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1